pH-Sensitive Hydrogel Copolymers for Oral Factor VIII Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic proteins orally face significant challenges due to the body's acidic and proteolytic environment, leading to low bioavailability and the need for invasive injection administration, which is inconvenient and costly.
Innovation Solution
Development of pH-sensitive hydrogel copolymers composed of methacrylic acid and poly(ethylene glycol) monomethyl ether monomethacrylate crosslinked with tetra(ethylene glycol) dimethacrylate or poly(ethylene glycol) dimethacrylate, which protect therapeutic proteins like factor VIII or IX from degradation and release them in the small intestine, enhancing oral delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic proteins are administered orally, then patient convenience and treatment cost are improved, but bioavailability is reduced due to degradation in the acidic and proteolytic environment
Solution Approach 1:
The patent uses pH-sensitive hydrogel copolymers as intermediary carriers to protect therapeutic proteins from degradation in the gastrointestinal tract. The hydrogel matrix serves as a protective intermediary that shields the protein from acidic and proteolytic environments during transit through the stomach and intestine, enabling oral administration while maintaining protein integrity and bioavailability.
Solution Approach 2:
The patent exploits pH parameter changes in the gastrointestinal tract to control hydrogel swelling and drug release. The hydrogel remains collapsed in the acidic stomach environment (pH 1-3), protecting the protein, then swells in the neutral-to-basic small intestine environment (pH 6-8), releasing the therapeutic protein when conditions are favorable for absorption.
2Stability of the object's composition
If pH-sensitive hydrogels are used to protect therapeutic proteins, then protein stability is improved, but delivery capacity for high molecular weight proteins is reduced
Solution Approach 1:
The patent employs composite hydrogel materials composed of methacrylic acid and poly(ethylene glycol) monomethyl ether monomethacrylate crosslinked with tetra(ethylene glycol) dimethacrylate or poly(ethylene glycol) dimethacrylate. This composite structure combines the pH-sensitivity of methacrylic acid with the biocompatibility and hydrophilicity of PEG, creating a matrix that can simultaneously protect proteins and accommodate high molecular weight therapeutic proteins like factor VIII and factor IX.
Solution Approach 2:
The hydrogel forms a porous three-dimensional network structure that can accommodate and protect high molecular weight proteins. The crosslinked polymer matrix provides a porous environment that maintains protein stability while allowing sufficient space and accessibility for large therapeutic proteins, overcoming the size limitations of previous hydrogel systems.
3Reliability
If repeated injections are administered to maintain therapeutic protein levels, then treatment effectiveness is improved, but patient quality of life and treatment cost are worsened
Solution Approach 1:
The patent implements preliminary protection of the therapeutic protein by encapsulating it within the pH-sensitive hydrogel matrix before oral administration. This preliminary action of encapsulation ensures the protein survives the harsh gastrointestinal environment, enabling a single oral dose to achieve and maintain therapeutic levels, thereby eliminating the need for repeated injections and improving patient quality of life.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel copolymers effectively protect and release therapeutic proteins in the intestinal environment, improving bioavailability and allowing for oral administration of high molecular weight proteins, potentially reducing the need for injections and lowering treatment costs.
Implementation Method 1
pH-sensitive hydrogels that may be used to deliver large molecular weight therapeutic proteins to a subject
Data Source
AI summary
In some aspects, a composition comprising a pH-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor VIII or factor IX. In some embodiments, the composition is orally administered to a patient to treat a disease or disorder such as, e.g., hemophilia.